Table 1.
Characteristics of Medicare beneficiaries initiating antihypertensive medication, by calendar year.
| Calendar Year | |||||||
|---|---|---|---|---|---|---|---|
| Characteristic | 2007 n=6,350 |
2008 n=7,379 |
2009 n=7,083 |
2010 n=6,947 |
2011 n=6,749 |
2012 n=6,627 |
p-trend |
| Mean age, years | 76.6 (7.4) | 76.7 (7.5) | 76.3 (7.3) | 76.0 (7.4) | 75.9 (7.5) | 76.2 (7.5) | <0.001 |
| Age group, years | |||||||
| 65–69 | 20.6 | 20.4 | 22.0 | 23.5 | 25.1 | 23.2 | <0.001 |
| 70–74 | 24.4 | 24.8 | 24.6 | 25.4 | 24.4 | 25.5 | 0.264 |
| 75–79 | 21.7 | 20.4 | 20.2 | 19.7 | 19.3 | 19.2 | <0.001 |
| 80–84 | 17.5 | 17.0 | 17.8 | 16.3 | 15.6 | 15.9 | <0.001 |
| 85+ | 15.9 | 17.4 | 15.3 | 15.1 | 15.6 | 16.3 | 0.267 |
| Male | 36.5 | 37.1 | 38.3 | 39.6 | 40.4 | 40.7 | <0.001 |
| Race/ethnicity | |||||||
| White | 80.6 | 81.8 | 82.1 | 83.4 | 83.9 | 83.7 | <0.001 |
| Black | 10.1 | 9.7 | 8.4 | 8.3 | 8.4 | 8.6 | <0.001 |
| Hispanic | 3.5 | 3.3 | 3.7 | 3.0 | 2.8 | 2.5 | <0.001 |
| Asian | 2.9 | 2.7 | 3.2 | 2.9 | 2.3 | 2.6 | 0.072 |
| Other | 2.9 | 2.6 | 2.6 | 2.4 | 2.5 | 2.6 | 0.272 |
| Antihypertensive drug class initiated |
|||||||
| Thiazide-type diuretic | 23.9 | 24.2 | 23.0 | 21.9 | 21.7 | 21.1 | <0.001 |
| Calcium channel blocker | 17.8 | 17.7 | 17.1 | 16.6 | 16.9 | 18.3 | 0.913 |
| Angiotensin converting enzyme inhibitor |
32.6 | 30.5 | 32.7 | 32.6 | 34.1 | 32.6 | 0.018 |
| Angiotensin receptor blocker |
14.8 | 15.4 | 14.7 | 15.0 | 14.3 | 13.9 | 0.034 |
| Loop diuretic | 10.5 | 10.9 | 10.4 | 10.5 | 10.7 | 11.1 | 0.486 |
| Beta blocker | 26.6 | 26.2 | 26.0 | 26.9 | 26.5 | 27.6 | 0.114 |
| Other | 8.0 | 8.6 | 8.3 | 8.6 | 8.2 | 7.1 | 0.035 |
| Single/Multiclass | |||||||
| Single Class | 71.3 | 72.0 | 72.8 | 73.3 | 72.9 | 73.9 | <0.001 |
| Multiclass/multiple pill | 12.0 | 12.1 | 12.0 | 11.8 | 12.6 | 12.6 | 0.221 |
| Multiclass/Combination therapy |
16.7 | 15.9 | 15.2 | 15.0 | 14.5 | 13.5 | <0.001 |
| Initiated with a 90 day fill | 17.3 | 19.3 | 23.4 | 28.5 | 31.7 | 33.7 | <0.001 |
| Year before initiation | |||||||
| Medicaid buy-in | 25.6 | 21.5 | 21.9 | 20.3 | 20.2 | 20.4 | <0.001 |
| Dementia | 10.5 | 10.9 | 10.6 | 10.6 | 11.2 | 10.2 | 0.758 |
| Diabetes | 26.3 | 26.3 | 27.3 | 28.0 | 28.7 | 29.1 | <0.001 |
| Coronary heart disease | 20.0 | 18.9 | 19.2 | 19.3 | 20.4 | 21.7 | <0.001 |
| Stroke | 7.0 | 6.8 | 6.0 | 6.1 | 5.8 | 6.6 | 0.039 |
| Chronic kidney disease | 10.1 | 10.4 | 11.8 | 13.2 | 14.0 | 15.7 | <0.001 |
| Heart failure | 9.5 | 9.3 | 8.3 | 8.8 | 9.4 | 9.0 | 0.596 |
| History of depression | 24.6 | 25.1 | 24.7 | 26.3 | 27.1 | 27.5 | <0.001 |
| Falls | 5.1 | 5.3 | 5.2 | 5.2 | 4.8 | 5.2 | 0.706 |
| Polypharmacy | 20.5 | 19.8 | 20.3 | 22.2 | 22.3 | 22.8 | <0.001 |
| Medicare part D coverage gap |
19.0 | 20.2 | 20.5 | 20.6 | 19.6 | 19.5 | 0.968 |
|
Six months after initiation |
|||||||
| Medicaid buy-in | 2.4 | 2.3 | 2.5 | 2.2 | 2.1 | 2.0 | 0.059 |
| Newly diagnosed dementia |
2.4 | 2.6 | 2.4 | 2.3 | 1.8 | 1.9 | <0.001 |
| Newly diagnosed diabetes | 1.8 | 2.2 | 1.9 | 2.1 | 1.8 | 1.6 | 0.117 |
| Newly diagnosed coronary heart disease |
4.3 | 3.8 | 3.8 | 3.8 | 3.7 | 3.4 | 0.013 |
| Newly diagnosed stroke | 2.0 | 1.7 | 1.6 | 1.5 | 1.5 | 1.4 | 0.008 |
| Newly diagnosed chronic kidney disease |
3.5 | 3.6 | 3.9 | 4.1 | 4.2 | 4.0 | 0.018 |
| Newly diagnosed heart failure |
0.4 | 0.3 | 0.5 | 0.4 | 0.3 | 0.4 | 0.935 |
| Newly diagnosed depression |
6.7 | 6.3 | 6.3 | 5.9 | 6.4 | 6.0 | 0.163 |
| Falls | 1.9 | 1.6 | 1.7 | 1.8 | 1.8 | 1.8 | 0.688 |
| Polypharmacy | 12.1 | 13.2 | 12.7 | 12.0 | 12.1 | 12.8 | 0.770 |
| Medicare part D coverage gap |
8.7 | 6.5 | 5.7 | 5.3 | 5.1 | 4.1 | <0.001 |
Numbers in table for age are mean (standard deviation) and percent for all other characteristics.
Multiclass=Incident prescription fill for ≥2 medications within 7 days.